Canaccord raised the firm’s price target on Inari Medical (NARI) to $74 from $71 and keeps a Buy rating on the shares. The firm said they reported a beat-and-raise in Q3 with $153.4M driven by its core VTE market. Baird also noted Inari will present its highly anticipated PEERLESS trial, which aims to convert CDT-treated intermediate-high risk PE patients onto FlowTriever/mechanical thrombectomy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NARI:
- Inari Medical price target raised to $67 from $66 at Baird
- Inari Medical price target raised to $52 from $50 at Piper Sandler
- Inari Medical raises FY24 revenue view to $601.5M-$604.5M from $594.5M-$604.5M
- Inari Medical reports Q3 EPS (31c), consensus (11c)
- NARI Earnings this Week: How Will it Perform?